Your pop up blocker may be preventing the MarketSmith tool from opening.
Learn how to resolve this issue.
Here is an idea for a long term holding MNEL.
Some others I consider value plays are CRVP, FVE, CBLI,DF,CLF,ETN,RTN.MOC, OMN,POL & UWN which i forgot to include in the list. All of these for me are long term holdings for at least five years or more.
I'll start posting over here since I lost my thread on investors.com location..to many Rons and Ron's I guess.
Take a look at the weekly for TGC. Ready to pop on the crossover.
SKBI is also a value play. Cash Flow of $2.14 PE of 1, .31 of book, Nice ROE. Getting ready to crossover.
Woops the stock is SKBI Is there value here? I think so P/E 1, 22% ROE , Cash flow +$2, Peg .25, $0.53 cash/share running at a profit margin of 29%.
TA reports 2/15... Monthly charts looks good.
They came in with blow out earnings this morning $1.10 compared to $0.07 year ago and also Q3 was only $0.07! PEG on this is only .5! Great value.
EFOI is on the move today breaking out above it's 265 DMA.
$PVFC is on the move breakout above the 265 DMA. I expect this one to double.
US PTO granted new patent claims relating to tobacco curing tech.
ROE on this is 52.6%, PE 8.26, Lots of cash per share. Earnings are expected to be up 90% this year. Guess the low number of shares scares folks away. I know this it has made me some serious money.
buy kors man :)
Bruce I am sure I will be able to buy KORS a lot cheaper than it is now in a couple of months. $0.67 Est EPS for 2012....look out below!
Riding the upper BB's. Looking good.
News out this morning moving this stock today. Up 40% today.
TA TravelCenters of America LLC Enters Memorandum of Understanding with Shell to Create a Network of Natural Gas Fueling Lanes Along the U.S. Interstate Highway System. News out this morning
TA out with 2Q EPS today..came in at $1.04. Big volume spike. This is a real value play and IMHO has a lot of upside potential.
Nanologicx is breaking out from a very long base. Check out the news on this one. It was up 26% today. Certainly not a CANSLIM stock but one I am making money on.
NanoLogix Rapid Diagnostic Technologies Set to
Enter Market Under FDA 510K-Exempt Status
Third-Party results on
accelerated Tuberculosis detection and rapid Group B Streptococcus
identification in pregnancies submitted for
Hubbard, OH, August 21,
2012 – NanoLogix
(OTC Markets: NNLX), a biotechnology innovator in the rapid detection and
identification of live-threat bacteria and microorganisms, announces it will
begin commercialization of its BNP (BioNanoPore) and BNF (BioNanoFilter)
diagnostic kits under FDA 510K-exempt status. The first product to be marketed
will be the Petri-based BNP detection kit utilizing TSA media. Other nutrient
media will be available by special order. Recently completed independent
third-party research has demonstrated BNP diagnostic kits to be two to ten times
faster at live bacteria detection than traditional methods. Following the BNP
rollout, NanoLogix plans to commercialize its BNF technology, which third-party
research documents as 18 to 72 times faster than conventional detection and
identification methods. The company also plans to develop customized test kits
for particular applications and client partners. NanoLogix is also
beginning sales of conventional TSA Petri plates. Both BNP kits and NanoLogix
TSA Petri plates will be packaged in the company's proprietary inert-gas charged
vacuum Flat Packs. A major third-party laboratory has documented these Flat
Packs to have at least a one-year shelf life stored under normal conditions,
compared to the 3-month shelf life of traditional Petri plates.
Peer-Reviewed Research Pending PublicationThe
results of two independent third-party research studies using NanoLogix
technology have been submitted by their respective organizations to major
peer-reviewed medical technology journals for publication.The first
submission details the use of NanoLogix BNF test kits and final results of a 356
pregnant-patient Group B Streptococcus (GBS) clinical study at the University
of Texas Health Science Center - Houston. This study attained GBS
detection, identification andantibiotic-sensitivity results from samples
collected in as little a 6 hours, a sharp contrast to traditional laboratory
test times of 48-72 hours. One major goal in the study was to ensure the
ability to test for antibiotic sensitivity in reduced time from the standard,
potentially enabling physicians to rapidly tailor antibiotics to the specific
infection involved and reduce the overuse of broad spectrum antibiotics. For
more on GBS:
second submission features data from a major independent laboratory documenting
NanoLogix BNP test kits five-day detection of live Tuberculosis. Traditional
culture delivers results in 21-28 days.
Inc.NanoLogix is a biotechnology company focused primarily on
rapid diagnostics. Its products offer accelerated detection and identification
of microorganisms. In addition to medical and homeland security applications,
NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and
environmental testing. Patents granted to NanoLogix can be used in the areas of
applied microbiology, soil microbiology and bioremediation, microbial
physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic
sensitivity. For more information visit www.nanologix.com.Media
Contact:Technica CommunicationsLisa Ann
Inc.firstname.lastname@example.orgThis press release
contains statements, which may constitute "forward- looking statements" within
the meaning of the Securities Act of 1933 and the Securities Exchange Act of
1934, as amended by the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or current
expectations of NanoLogix, Inc., and members of its management as well as the
assumptions on which such statements are based. Prospective investors are
cautioned that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking statements.
The Company undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of unanticipated
events or changes to future operating
Massive volume today up 18% crossover!
Here is another one that seems to me to be a real value play. Started a small position.
Title: Neuralstem Completes Phase I ALS Stem Cell TrialDate(s):
27-Aug-2012 9:02 AMFor a complete listing of our news releases, please
Keep an eye on this one. Should make for a nice return for someone that has a little be of time to hold it.
TV news story from FOX Atlanta on CUR. This is great news for this stock.
This one has great long term potential to be a huge gainer. PEG of 0.56 P/B 0.37.
Can't figure out why this one doesn't have a lot of demand behind it. Nice P/B, Cash flow is good. Lots of bets on a lower price with the shorts drooling.
This has had a nice move up. Also holding FEED which has had a pretty nice return on my investment.
Stage 1 base building 10% to pivot.
May want to take a look at TPI out with fiscal year earnings of $0.22 on a $0.55 priced stock. Trading at 0.19 book with cash per share of $1.02! Oh well I like it even if no one else does...grin.
News out this morning!
CLEVELAND, Oct. 2, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) recently completed enrollment of the first patient cohorts of its Phase 2 study of MultiStem®, a novel adult stem cell therapy being developed by Athersys,
administered to patients within approximately 1 to 2 days after they
have experienced an ischemic stroke. The independent safety committee
reviewed data from these patients, finding that both of the doses
evaluated were safe and well tolerated, and therefore, recommended
proceeding with high dose administration to patients for the remainder
of the trial.
Phase 2 study is a double blind, placebo-controlled trial evaluating
the safety and efficacy of MultiStem when administered to patients who
have suffered a moderate to moderately severe stroke, as defined by a National Institutes of Health Stroke Scale (NIHSS)
score of 8 to 20. Patients enrolled in the study receive a single
intravenous dose of MultiStem therapy or placebo in the 24 to 36 hours
following the stroke, which is a significant extension of the current
treatment window over existing standard of care. The study is currently
being conducted at multiple centers throughout the United States.
are very excited about the initial results from this program and
believe that it could represent a major advance in clinical care for
ischemic stroke patients. We believe MultiStem has the potential to
significantly enhance patient recovery, as well as meaningfully extend
the treatment window over the current standard of care for stroke
victims, enabling many more patients to receive treatment," said Dr. Gil
Van Bokkelen, Chairman and Chief Executive Officer of Athersys. "We are
pleased with the results from the initial phase of the study, including
the additional evidence of a consistent safety profile for MultiStem,
and we intend to move the program forward aggressively to completion."
first part of the Phase 2 study included two cohorts, with each cohort
including a placebo group and a treatment group — a low dose of
MultiStem in the first cohort and a higher dose in the second
cohort. The third cohort has a placebo group and treatment group,
randomized 1 to 1. The study is expected to enroll approximately 136
patients in total.
safety endpoints for the trial include measuring acute infusional
reactions over the first 7 days following treatment. Primary efficacy
measures include determining the proportion of patients with a modified Rankin Scale of
0 to 2 (which represents patients capable of independent living) at day
90 in the MultiStem treatment group compared to subjects in the placebo
treatment group. Secondary endpoints include functional outcome as
determined by NIHSS score and Barthel Index. The study includes
additional exploratory endpoints, such as measuring stroke infarct size
and blood marker changes between the MultiStem and placebo treatment
believe that development of a safe and effective therapy for ischemic
stroke represents both a major clinical and commercial opportunity, and
one that could drive value for our shareholders," added Dr. Van Bokkelen. "We believe that this Phase 2 study will provide compelling evidence of the potential of the program."
Getting ready to breakout with a cross over.
May want to take a look at GURE. There appears to be a bull/ bear battle going on. Short interest is high with 32 days to cover! The chart looks like it may want to take off.
Cup & Handle on PVFC and below the pivot.
Breaking out this morning.
Good Morning Ron, et al;
Like you, have been investing in NanoLogix for a while. Any thoughts on the new Science Advisor, Dr. Giles Manley? Seems to me Nano is working to get the two peer-reviewed papers published, then start it's marketing push. Dr. Manley seems very well qualified and connected to help present the technology at high levels. Stock chart also again appears to be basing.
Here is the recent news:
10.21.12 Nanologix News: NanoLogix is pleased to welcome Giles Manley, MD to its Science Advisory Board.
Giles Manley, M.D.
Dr. Manley brings to the Science Advisory Board more than 20 years
experience in the medical profession. As a Board Certified OB/GYN with
well over 2,000 deliveries, he is extremely knowledgeable in all areas
of obstetrics. His specialty training was at the Greater Baltimore
Medical Center (GBMC), which included a four-month rotation of high risk
obstetrics at Johns Hopkins Hospital. Following successful completion
of his residency, he served as a faculty instructor at GBMC, as well as
maintaining a private practice. In 1996, he left this practice to become
the Chief of Obstetrics and Gynecology in Baltimore for the
Mid-Atlantic Permanente Medical Group (the physician group of Kaiser
Permanente). In addition to serving as OB/GYN Chief, in 2002, he also
took on the role of Area Medical Director.
In addition to his extensive obstetrical experience, Dr. Manley also had
a particularized interest in gynecologic surgery. His specialty was in
the area of minimally invasive procedures. He was the first person at
GBMC to perform a laparoscopic supra cervical hysterectomy, as was he
the first to perform incontinence surgery utilizing a tension free
vaginal tape. Both procedures allowed the patient to go home the day of
surgery with only a one to two week recovery. He has lectured to
physicians nationwide about these innovative techniques.
Throughout his medical career, Dr. Manley has served on a number of
committees, including; the Obstetrical Advisory Committee at GBMC, the
Gynecology Advisory Committee at GBMC, the Obstetrical Quality Review
Committee at Kaiser, to mention a few. He is a fellow of the American
Board of Obstetrics and Gynecology as well as the American Congress of
Obstetrics and Gynecology.
Dr. Manley is a member of the Maryland Bar. He was elected Member of the
Year in Madison Who's Who Registry of Executives and Professionals for
2007-2008 edition, and was also selected to its Round Table, honoring
Dr. Manley as one of the top 100 members worldwide.
Since this is an investment message board, per the reply regarding Dr. Giles Manley, here are some posts on the Yahoo - Nanologix message board from a giles_manley.
Including: "Re: NNLX....
a very good opinion at that! It sounds like they already have
positioned themselves for mass production, including the new patent on
They could probably get $3-5/share now in a buyout or, if everything
falls in place, be a company trading at ??????$50-100/share in a few
years. There is noting comparable to their technology and pricing
(although I certainly worry about some of the giants in the market
scrambling to find something comparable)in a $44 billion dollar market.
I firmly believe they will be first to offer their product on the open
market, and when that happens, I don't see any way that the majority of
that $44 billion doesn't come their, and our, way!
Just bought another 30,000 shares at .48 and .49!
In process of freeing up more money!".
"Re: Bashers Treading Water
just want to say I discovered this company over 3 years ago. I own
several hundred thousand shares, and have not sold 1.
I was an Ob/Gyn for 20 years, and know the dangers of GBS. This is one
technology, finally, that I am very familiar with. If I had to
estimate, this company will be bought out somewhere in the next 1-3
years between $8-10/share. There is nothing even close on the market,
and soon every pregnant woman will be tested using there technology,
GBS in infants is devastating! Currently pregnant women are tested
between 32-36 weeks gestation. The problem is that this infection comes
and goes in a woman's vagina, so a negative test 5 weeks before
delivery tells you nothing about what's there at the time of labor. We
test this way now because it is better than nothing, but having the
results within 4 hours of labor will absolutely be the gold standard!
This company is not like many other whims I've seen on these message
boards...remember Jammin Java or Raystream.
So cheers to those believers...hold on to your shares!".
Reposting from Investors dot com post:
Been pretty quiet here, but FYI The EPA recently came out with a
Featured Update for NanoLogx on their website, and was featured in the
NanoLogix PR yesterday.
Also quoting from the PR:
of the CRADA is to develop a comprehensive water quality test kit for
use in testing drinking and source waters in the EPA’s ten regions.
The article can be accessed on the EPA’s site at the following link: http://www.epa.gov/nerl/features/nanologix.html"
"NanoLogix is honored to welcome Giles Manley, MD to the NanoLogix
Science Advisory Board (SAB). Dr. Manley brings a wealth of medical,
legal and business knowledge to the SAB.
Dr. Manley’s acceptance statement: “I am grateful for the invitation,
and very excited about being part of NanoLogix by serving on their
Science Advisory Board. What NanoLogix has accomplished over the last
several years is truly amazing. There is no comparable system in the
world that can deliver bacterial identification as cost effectively,
quickly and accurately as their BNF and BNP product line… Through my
career I have formed acquaintances with the Chiefs of Obstetrics at some
of the top medical institutions in our country. I will make a concerted
effort to get the necessary trials started and finished at places such
as Harvard, Johns Hopkins and other institutions. I am hopeful that by
the end of 2013 the standard for GBS screening will include our near-15
minute test at time of labor.”
More information on Dr. Manley and the SAB can be found at: http://nanologix.com/about/team.html "
Therefore new information on the 15 minutes GBS test!
Previously had seen a 'less than 1 hour" result but 15 minutes is very
interesting as is Dr. Manley's comments on new Trials - this becoming
the standard for GBS screening.
Fully admit it's still early days, but seeking any legal information advantage that I can find! Share price made some wild swings in the past week as still low price and thinly traded.
Petro there are a lot of under the radar stocks out there waiting to be discovered. I guess we need to see some EPS on this one to move it.
Take a look at MJNA. Came in with EPS of $0.06 this morning, 34.3 million shares traded today. Net income has been growing. For sure not a CANSLIM stock, interesting none the less.
Still huge trading volume. 6.2 millions shares by 10:30. Price is holding up nicely.
Lots of large blocks coming through on this one. 15.8 million shares so far today. Certainly is under accumulation IMHO.
An easy double your money stock. Running up the flag pole.
This seems like a great value play trading at book value with a reasonable PE. Earnings due out Monday 3/4. I believe that it will double in price in next few months.
I like the monthly chart on this one. Clean EPS 4Q $0.43 for the year $1.35. Seems like great value.
HUBBARD, Ohio, Mar 12, 2013 (BUSINESS WIRE) -- Insert inside the quotation marks in the first graph, first sentence of release: Infectious Diseases in Obstetrics and Gynecology
Please also embed with the URL: http://www.hindawi.com/journals/idog/2013/367935/
The corrected release reads:
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON RELEASES NEWS OF SUCCESSFUL NANOLOGIX TEST
UTHealth researchers say more rapid test for Group B strep successful
NanoLogix Inc. (NNLX), an innovator in the accelerated detection, identification and antibiotic sensitivity determination of live bacteria, announces that final results of a 14 month study done by researchers at UTHSC-Houston have been published in a recent online edition of "Infectious Diseases in Obstetrics and Gynecology." The results were also presented at the 33rd annual Society of Maternal Fetal Medicine meeting last month in San Francisco. Researchers tested 356 pregnant patients for Group B Strep using NanoLogix BNF tests during the study, with NanoLogix test results obtained in 6.5 hours as opposed to 48 hours with standard tests.
Jonathan Faro, MD, PhD, the chief researcher on the study and assistant professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at The University of Texas Medical School at Houston, part of UTHealth, stated: "We're very happy at UT to have the recent clinical study on GBS showing positive results with the 6.5 hour test. Even more exciting, however, is that we are now seeing results as fast as 30 minutes. This more rapid test is based on a modification of the 6.5 hour test, and has the potential to allow for antibiotic susceptibility testing in an amount of time that would have previously been considered simply impossible. The studies with GBS have been applied to other bacteria, and we are very pleased to see similar results with gonorrhea, which has been implicated last year as a multi-drug resistant pathogen. We are in the final stages of formalizing the 30 minute test for GBS, and will continue to work on additional applications for this assay."
The news from UTHealth Houston can be found here: http://www.uthouston.edu/media/story.htm?id=e3142cc6-bc5b-415d-8f17-8243da5eb58d
NanoLogix exhibited at the ASM BioDefense and Emerging Diseases Research Meeting in Washington DC 25-27 February 2013. There was strong interest in the Company's technologies at the exhibition. Interested parties included Federal agencies, universities, large and small laboratories, NGO's, and corporations, with resulting sales begun this week.
NanoLogix has contracted with a team of independent marketing specialists to promote the Company's products to key opinion leaders and executives in multiple health and food sectors. The specialist team is composed of current or former directors and managers of various national and international health sector corporations. This event marks the transition of the Company from a primary focus on research and development to one of marketing and production. There will be a continued science emphasis upon water quality test development with the US EPA and also product QA/QC. This new focus will also result in a reallocation of resources with a heavy focus upon increased marketing on multiple fronts.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to national defense, medical, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, food quality, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.
For more information visit http://www.nanologix.com .
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
SOURCE: NanoLogix Inc.
Carol Surrena, 330-534-0800
Copyright Business Wire 2013
1Q Earnings and revenue out. If my math is right !Q EPS is $0.1054 compared to 4Q EPS of $0.06.
Receives FDA Approval To Commence Phase II Stem Cell Trial In Amytrophic Lateral Sclerosis or ALS!
Neuralstem, Inc. has added four news articles to its website.
U-M May Recruit ALS Patients for Stem Cell Clinical Trial
FDA Approves Stem-cell Trial for ALS Patients at UM
ALS Stem Cell Trial Expanding to U-M
FDA Clears U-M Stem Cell Clinical Trial to Recruit ALS Patients
Articles Date: 17-APRIL-2013
"We need ALS research fast-tracked... This isn't even about a cure. People would be happy with the treatment." NSI-566/ALS principal investigator, Eva Feldman, M.D., Ph.D. spoke withDetroit Free Press's medical writer Robin Erb in a follow-up feature story. Ms. Erb is one of three Detroit-based reporters covering the Phase II approval by the FDA.
FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
Another story out today. Extremely heavy volume today on the news.
Title: Neuralstem Completes Phase I ALS Stem Cell TrialDate(s):
27-Aug-2012 9:02 AMFor a complete listing of our news releases, please
If you had bought 8/12 ish you would be up 175% right now. Still a great value @ 1.60 and I think it will be well above $2.00 in the not too distant future. Still working on the Phase II so look out if Phase III hits.
Lots to like about this stock
Another Chinese stock with upside potential.
An interesting stock or really a hedge fund. Pays a good dividend.
Should move today on strong Revenues.
Earnings out WOW!
Keep an eye on this one. Earnings are due any day and I expect a blowout number. Beautiful Chart too.
Chinese stocks are good buys for the most part. Their economy is still growing in the 7% area. The consumers will carry their market for the next 5 years. I like GURE JST LAS LIWA SKBI SPU TPI.
Since the Justice Department is keeping it hands off marijuana, and leave it up to states. I believe the upside potential is tremendous. I know I had a good day yesterday almost 50 millions shares traded.
Orphan drug status is helping move this along. Another new high today. I hope some you jumped on the train for a great ride so far.
Finally a product being sold!
Cup and handle on the daily chart on heavy volume today.
ron.kimmich wrote the following post at 02-23-2012 8:21 AM:
If you bought back in 2/2012 and held it you'd be up 300+%. The stock market is a great place to be.
Up 10% on heavy volume caused by upgrade with a TP $3.00. I have been a long term holder for grand kids college fund.
Philadelphia, PA, Tuesday, January 21, 2014: Hemispherx Biopharma (NYSE MKT: HEB), today announced that Dr. William M. Mitchell of Vanderbilt University will present a research paper on January 21, 2014 at the Keystone Symposia Conference on Pathogenesis of Respiratory Viruses entitled “Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus (H5N1) by Low Dose Natural Human IFN-α Administered to the Buccal Mucosa.” This presentation is a collaborative project conducted at Viroclinics, Rotterdam, an internationally recognized research entity for the study of both seasonal and pandemic influenza viruses. The facilities are directed by Prof. Albert D.M.E. Osterhaus, an internationally known virologist specializing in the study of pandemic influenza. The global threat of an influenza pandemic emerging from avian H5N1 and H7N9 influenza viruses that are highly pathogenic for humans has mobilized a variety of efforts to mitigate the potential devastating human and economic consequences. A key element in governmental responses has been neuraminidase inhibitor stockpiling for therapeutic or prophylactic uses although the development of viral resistance without loss of viability is a constant threat to their human employment. Using an established primate model for H5N1 infection, the collaborative team has evaluated the potential for the prophylactic mitigation of the pulmonary damage characteristic of fatal cases from primary influenza virus pneumonia using a low dose oral (LDO) formulation of a commercially available parenteral natural human interferon alpha (Alferon N Injection®). About Viroclinics Biosciences, BVViroclinics Biosciences is a leading diagnostic and clinical trial operation service company providing diagnostic and preclinical studies along with drug development for prevention and treatment of virus infections.Its mission is to improve human and animal health by serving the biopharmaceutical industry with state-of-the-art diagnostics, operational and logistical services, custom-made models in preclinical and clinical drug testing, and expert advice on development of antivirals and vaccines. It offers a full range of virology services for new drug development programs and post-marketing surveillance of existing drugs and vaccines, ranging from traditional virology assays to the latest deep sequencing protocols for a very broad range of viruses.Its BSL2 and BSL3 labs enable it to perform analysis according to international ISO 15189 accreditation expanded with elements of GLP and GCP. The ongoing, intimate interaction between scientists at the Erasmus MC and company staff yields a strong, flourishing platform to act and implement assays at the forefront of Viroscience.About Hemispherx BiopharmaHemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because both Ampligen® and Alferon® LDO are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®), approved for sale in the U.S. and Argentina. The Company’s Alferon N approval in Argentina includes the use of Alferon N Injection (under the brand name “Naturaferon”) for use in any patients who fail or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net. Competing Interests Disclosure: Dr. William Mitchell, Prof. of Pathology, Microbiology and Immunology at Vanderbilt University is a member of the Board of Directors of Hemispherx Biopharma, Inc. and is a shareholder in the Company.
Company/Investor Contact:Charles Jones CJones & Associates Public Relations888email@example.com
Forward-Looking StatementsTo the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “potential,” “potentially,” “expects,” “may” and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Hemispherx that any of its plans will be achieved. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Hemispherx’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Examples of such risks and uncertainties include those set forth in the Disclosure Notice, above, as well as the risks described in Hemispherx’s filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Hemispherx undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise revise or update this release to reflect events or circumstances after the date hereof.
Running below the radar. Up 29% yesterday with 82 million shares traded.
1/28 less than 3 hours into trading and we have 46.3 million shares traded. up another 17.5%
Here is another value stock. Below the radar. I also like CXDC as a value play at a reasonable price.
Net income for the fourth quarter of 2013 was $13.2 million, or $0.44 per share, compared with net income of $15.8 million, or $0.52 per share, for the fourth quarter of 2012. Per share figures for both the 2013 and 2012 periods are based on 30.0 million weighted average diluted shares outstanding.
Non-GAAP net income for the fourth quarter of 2013 was $13.3 million, or $0.44 per diluted share, compared with non-GAAP net income of $15.9 million, or $0.52 per diluted share, for the fourth quarter of 2012. Non-GAAP net income excludes the aggregate impact of warrant-related non-cash loss of $0.05 million and $0.1 million in the fourth quarters of 2013 and 2012, respectively.
Adjusted EBITDA for the three months ended December 31, 2013 was $19.1 million, compared with $22.9 million for the same period in the prior year.
Summary 2013 Financial Results
Revenue for 2013 was $900.7 million, compared with $853.8 million for the full-year of 2012. For the full year of 2013, gross profit was $86.4 million, net income was $56.2 million and diluted earnings per share were $1.87. Non-GAAP net income was $56.3 million for 2013 and non-GAAP diluted earnings per share were $1.88 for the year. Adjusted EBITDA for 2013 was $80.0 million.
Balance Sheet and Cash Flow
As of December 31, 2013, Lihua had $203.4 million, or $6.78 per diluted share, in cash and cash equivalents, compared with $144.3 million, or $4.82 per diluted share, as of December 31, 2012. Cash flow from operations for 2013 was $61.0 million, compared with cash flow from operations of $48.7 million in 2012. As of December 31, 2013, Lihua had working capital of $274.6 million and no debt.
"Given the slowdown in China's economy and current infrastructure spending, we expect modest growth on the top and bottom lines in 2014. We plan to gradually ramp up production and sales of our new higher margin CCA superfine wire product, but we don't expect to see substantial growth from the product in its first full-year. We remain cautiously optimistic about the economic outlook and copper supply and demand dynamics in China. As such, we expect full-year 2014 gross profit and non-GAAP net income to be in the range of $89-91 million and $58-60 million, respectively, representing year-over-year improvement of 3.0-5.3% and 3.0-6.6%," concluded Mr. Zhu.
Still a great value trading at 0.26 of book value, PE of 2 with EPS of 1.61 in 2013 for sure has put in a bottom.
Up as high as .45 in AH on Ebola news.
© 2014 MarketSmith, Incorporated. All Rights Reserved. MarketSmith® is a registered trademark of MarketSmith, Incorporated. All data provided by William O'Neil + Co. Incorporated unless otherwise noted.